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Risk for Sudden Cardiac Death Associated
With Marathon Running
As an avid runner and occasional marathoner, I was pleased to learn
that the risk of sudden death during or immediately after running a
marathon is very low (1). Unfortunately, I believe that the authors’
assessment of risk relative to other activities is somewhat misleading.
Assuming that there are 200,000,000 U.S. adults at risk for sudden
death, and that there are 500,000 sudden deaths annually, the risk of
sudden death or cardiac arrest as a function of living hours is
approximately 1 death/3,504,000 h. The rate reported by Maron et al.
(1) during or after a marathon, 1 death/215,000 h, is roughly 16-fold
higher than the rate during normal living.
Thus, although the risk of dying suddenly during a marathon is
quite low, it is still 16 times greater than the risk of sudden death
during all other living activities combined.
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Reply
We thank Rich for his comments. We certainly agree, based on our
recently published data (1), that the risk for sudden death directly
associated with long-distance or marathon running is indeed exceed-
ingly low (i.e., ;1 in 50,000). However, calculation of the overall risk
for premature death associated with living can prove to be a rather
complex and difficult undertaking. In our report (1) we chose to
calculate such values directly from U.S. Vital Statistics and the
National Center for Health Statistics for the years 1979, 1990 and 1991
(2). Perhaps this methodology accounts for the differences between
our published values (1) and the estimates offered by Rich in his letter.
BARRY J. MARON, MD, FACC
Cardiovascular Research Division
Minneapolis Heart Institute Foundation
920 East 28th Street, Suite 40
Minneapolis, Minnesota 55407
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Late Potentials in the Thrombolytic Era:
Time for Reevaluation?
We read with interest the report by Karam et al. (1). The authors
reported a decrease in the prevalence of late potentials with mechan-
ical reperfusion compared with thrombolysis after myocardial infarc-
tion. However, the report raises a number of important issues.
Although the significance of late potentials in the early phase
(,48 h) is unclear, El-Sherif et al. (2) found that only late potentials
recorded between days 6 and 30 were associated with arrhythmic
events. In particular, they recommended that “the optimal time
window for obtaining a signal-averaged ECG is between 6 and 14 days
after infarction.” However, the study by El-Sherif et al. predated the
thrombolytic era and excluded patients .79 years old. Although
Karam et al. justify their recording time on this study, they give only
the median time and neglect to give the range. A median recording
time of 11 days suggests that many recordings may have been made
after day 14, at which time late potentials have little prognostic
significance. Furthermore, the authors fail to give any data on arrhyth-
mic events or sudden death in the patients studied.
This leads to a more fundamental issue, which is the unproved role
of late potentials as a predictor of arrhythmic events in a thrombolyzed
cohort. Many of the pioneering studies referenced in the report
predate the thrombolytic era. The widespread use of thrombolysis and
early revascularization have significantly reduced the arrhythmic event
and mortality rates after acute myocardial infarction (3,4). These same
studies (neither of which is referenced) have failed to show a relation
between late potential development and arrhythmic events in a
thrombolyzed patient cohort.
We previously showed (5) that late potentials in the first 7 days
after acute anterior myocardial infarction (after thrombolysis) are
associated with an increase in ventricular volume at 6 weeks. In a
larger study of patients receiving thrombolyic therapy, Hohnloser et al.
(4) also found that late potentials were associated with wall motion
abnormalities. On the basis of our findings, we suggested that the
prognostic value of late potentials in the first week (and particularly on
day 3) may be related to ventricular dilation. Although Karam et al.
performed radionuclide left ventricular angiography in all patients, no
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